# QTERNMET XR
> **NDA210874** · New Drug Application · Sponsor: ASTRAZENECA AB · Approved 2019-05-02
## Drug
- **FDA Application Number:** NDA210874
- **Application type:** New Drug Application
- **Brand name:** QTERNMET XR
- **Generic name:** Dapagliflozin
- **Active ingredients:** DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** ORAL
- **Marketing status:** Discontinued
- **Sponsor:** ASTRAZENECA AB
- **First approval:** 2019-05-02
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210874)
---
*MORVS · CC0 1.0*